“Woah! It's like Spotify but for academic articles.”

Instant Access to Thousands of Journals for just $40/month

In Search of Better Prognostic Indicators for Patients with Oligodendrogliomas

In Search of Better Prognostic Indicators for Patients with Oligodendrogliomas Cancer Investigation, 14(3), 288-289 (1996) In Search o Better Prognostic Indicators for f Patients with Oligodendrogliomas E. G.Shaw, M.D. Departmentof Radiation Oncology Bowman Gray School of Medicine Winston-Salem,North Carohna27157 In this issue of Cancer Investigation, Peterson and Cairncross comprehensively review the epidemiology, clinical presentation, pathology, treatment, failure patterns, and prognosis of cerebral oligodendrogliomas.They describe a number of known diagnostic, pathological, and treatment-associated prognostic factors, including age, imaging-based contrast enhancement, extent of surgical resection, tumor grade, and the addition of radiation therapy and chemotherapy. In the current “molecular era” of medicine, what are the potential contributions of translational research to the diagnosis and treatment of oligodendrogliomas? Basic science investigations of these tumors have included assessments of ploidy, proliferation, and genetic factors. DNA content has no significant association with survival. Aneuploid oligodendrogliomashave comparable survival rates as diploid tumors (1-3). Proliferation,on the otherhand, as measured by the %S-. %G2M-,or %S+G2Mphase fractions, does significantly correlate with survival. In a study from the Mayo Clinic, the median survival time and 5-year survival rate were 9.5 years and 73%, respectively, in patients with an S-phase fraction of <6%, compared to 3.9 years and 39% for those with a 26% S-phase fraction. Coons et al. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Investigation Informa Healthcare

In Search of Better Prognostic Indicators for Patients with Oligodendrogliomas

Abstract

Cancer Investigation, 14(3), 288-289 (1996) In Search o Better Prognostic Indicators for f Patients with Oligodendrogliomas E. G.Shaw, M.D. Departmentof Radiation Oncology Bowman Gray School of Medicine Winston-Salem,North Carohna27157 In this issue of Cancer Investigation, Peterson and Cairncross comprehensively review the epidemiology, clinical presentation, pathology, treatment, failure patterns, and prognosis of cerebral oligodendrogliomas.They describe a number of known diagnostic, pathological, and treatment-associated prognostic factors, including age, imaging-based contrast enhancement, extent of surgical resection, tumor grade, and the addition of radiation therapy and chemotherapy. In the current “molecular era” of medicine, what are the potential contributions of translational research to the diagnosis and treatment of oligodendrogliomas? Basic science investigations of these tumors have included assessments of ploidy, proliferation, and genetic factors. DNA content has no significant association with survival. Aneuploid oligodendrogliomashave comparable survival rates as diploid tumors (1-3). Proliferation,on the otherhand, as measured by the %S-. %G2M-,or %S+G2Mphase fractions, does significantly correlate with survival. In a study from the Mayo Clinic, the median survival time and 5-year survival rate were 9.5 years and 73%, respectively, in patients with an S-phase fraction of <6%, compared to 3.9 years and 39% for those with a 26% S-phase fraction. Coons et al.
Loading next page...
 
/lp/informa-healthcare/in-search-of-better-prognostic-indicators-for-patients-with-Oijq0ErRGE

Sorry, we don't have permission to share this article on DeepDyve,
but here are related articles that you can start reading right now: